CN1313138C - 治疗帕金森氏综合征的中药制剂 - Google Patents
治疗帕金森氏综合征的中药制剂 Download PDFInfo
- Publication number
- CN1313138C CN1313138C CNB021266557A CN02126655A CN1313138C CN 1313138 C CN1313138 C CN 1313138C CN B021266557 A CNB021266557 A CN B021266557A CN 02126655 A CN02126655 A CN 02126655A CN 1313138 C CN1313138 C CN 1313138C
- Authority
- CN
- China
- Prior art keywords
- gram
- radix
- medicine
- rhizoma
- desiccation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 206010034010 Parkinsonism Diseases 0.000 title abstract 3
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- 241000208296 Datura Species 0.000 claims abstract 3
- 241000305492 Gastrodia Species 0.000 claims abstract 3
- 241000628997 Flos Species 0.000 claims description 7
- 241000237636 Pheretima Species 0.000 claims description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 241000255791 Bombyx Species 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 241000237903 Hirudo Species 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 241000005787 Cistanche Species 0.000 claims 2
- 241000931705 Cicada Species 0.000 claims 1
- 241000202807 Glycyrrhiza Species 0.000 claims 1
- 241000219780 Pueraria Species 0.000 claims 1
- 241000133425 Stauntonia Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002775 capsule Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 6
- 239000000706 filtrate Substances 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 206010012335 Dependence Diseases 0.000 abstract description 2
- 239000003390 Chinese drug Substances 0.000 abstract 3
- 241000361919 Metaphire sieboldi Species 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000036461 convulsion Effects 0.000 description 8
- 206010010904 Convulsion Diseases 0.000 description 7
- 208000005392 Spasm Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 206010015037 epilepsy Diseases 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 230000002048 spasmolytic effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 208000008765 Sciatica Diseases 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 description 2
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000772100 Thamnosma Species 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000003153 cholinolytic effect Effects 0.000 description 1
- 108010006161 conchiolin Proteins 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000001042 pteridinyl group Chemical class N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
天龙丹花胶囊是由天麻、地龙、丹参、洋金花等17味天然纯中药组成复方经提炼加工浓缩而成，属于中药散剂和滤液浓缩制作技术领域。该药是目前治疗帕金森氏综合征的特效药品，与目前同类药品相比，优点是天然纯中药浓缩制剂，服后不成瘾，对各组织器官无毒副作用。所要解决的制备技术问题是科学的浓缩和适宜的干燥。经采用原武汉中联制药厂的“真空浓缩”、“喷雾干燥”的方案，既解决浓缩中易产生沸溢现象；又解决干燥时不易烘干和影响药品资量的发生，同时，可以缩短制备工艺的流程，达到中药制剂能代替西药L-多巴多治疗帕金森氏综合征的目的和用途。
Description
天龙丹花胶囊是天然纯中药经提炼加工浓缩而成，属于中药散剂和滤液浓缩制作技术领域。经余多年实践研究和临床应用，表明该药对治疗三叉神经痛、坐骨神经痛、癫痫、颈椎综合征，特别是对治疗帕金森氏综合征等方面有一定疗效。
该药有活血祛瘀、扩张心脑血管、养血安神、解痉、镇痛、抗炎及抗惊厥功能，并有较强的解热、止痛、缓解肌肉痉挛等作用，还有改善机体免疫的能力。
该药比以前同类药品具备新颖性、创造性和实用性。
说其具有新颖性是该药从天然纯中药内精选浓缩提炼加工组成，服后不成瘾，对各组织器官、脏器无损害或毒副作用。截至目前国内外还未有公开发表用天然纯中药能治愈帕金森氏综合症的报道。
说其具备创造性，因在此之前治疗帕金森氏综合症的西药有依赖性，只是治标不治本。该药既治标又治本，免除开颅去黑质的高难立体导向手术。
说其实用性，该药品药源丰富，加工方便，不需繁杂的工艺，易生产易开发。
据1986年1月～2002年1月，治疗帕金森氏综合症50例，痊愈16例，占32％，显著好转20例，占40％；好转12例，占24％；无效2例，占4％；总有效率96％。
现对该药的内容、药理作用、制备工艺表述如下：
1、技术领域
属于中药散剂和滤液浓缩制作技术领域。
2、发明的目的和效果
治疗帕金森氏综合征，一周可控制症状发展；对伴有高血压、糖尿病、冠心病的患者随症加减用药可近快控制症状，一个月内达到治愈目的，其有效率达96％。
3、主要内容
(1)处方组成
炒白芍30克、丹参25克、鸡血藤20克、地龙、葛根、怀牛膝各15克，僵蚕、天麻、勾藤各12克，肉苁芸、大黄、蝉退、羌活、水蛭、甘草各10克，石决明24克，洋金花10克，共计生药250克。
(2)药物作用及功能
该药由活血化瘀、解痉、止痛、抗炎、抗惊厥、扩张外周血管、改善微循环、兴奋中枢神经和特殊中枢抑制作用三组药物组成。
①活血化瘀、解痉止痛、抗炎、抗惊厥作用。
丹参、鸡血藤、白芍、怀牛膝、地龙活血化瘀。白芍主治肝阳上亢、四肢拘挛，所含化学成分芍药甙又有解痉、镇静、镇痛及抗惊厥、抗炎作用。配合地龙的清热止痉，其化学成分含有多种氨基酸、琥珀酸，有降低血压和防治脑动脉硬化作用；鸡血藤为强壮性补血药，主治手足麻木，神经麻痹；又添怀牛膝含皂甙及多量钾盐，除活血祛瘀、通经、补肝肾、强筋骨外，还能引血下行，引热、引药下行；蝉退含蝶啶类色素，有散风热，定惊痫、镇静作用；又配僵蚕之息风解痉、抗惊厥作用更显著；天麻配石决明可平肝潜阳、熄风、定惊痫、止抽搐、定震颤；石决明含碳酸钙、胆素、壳角质，为拟副交感神经药。
②扩张血管、改善微循环
丹参配葛根扩张心脑血管冠状动脉，增加冠脉流量改善微循环。葛根配芍药并有较强的解热止痉、缓解肌肉强直痉挛。
③改善中枢神经功能，并对中枢神经系统有双向调解作用
勾藤配洋金花除镇痉止痛作用外，勾藤碱能兴奋呼吸中枢抑制血管运动中枢，扩张外周血管，有特殊中枢抑制作用的镇静药；洋金花味辛温有毒，现代药理报道，含东莨当碱及少许阿托品有抗胆碱作用，据临床实践证明能阻断大脑皮层感觉运动区神经原的M——胆碱受体，使内源性乙酰胆碱与受体结合，无法发挥递质功能，致使感觉和运动功能迅速抑制并有麻醉效果，并确实安全无毒副作用。加上大黄之泻火凉血、清热解毒；甘草甙之抗炎、抗过敏；丹参之活血化瘀，养血安神；配肉苁芸之滋补肝肾；更有羌活配葛根能兴奋脊髓中枢神经，善治头项、脊背及上肢痉挛疼痛。妙在水蛭素含有肝素及抗血栓素等蛋白质，并能消除黑质，可改善黑质纹状体通路变性，达到帕金森氏综合征彻底治愈。
4、主治及适应症
用于治疗帕金森氏综合征，癫痫、三叉神经痛、坐骨神经痛、颈椎综合征。
5、制备工艺
(1)筛选药物
将处方中的药材去杂质筛选上等药物，称足量。
(2)煎煮药液浓缩
取白芍、鸡血藤、丹参、葛根、肉苁芸、怀牛膝、石决明、甘草八味药水煎煮2次，第1次1.5小时，第2次1小时；大黄、勾藤、羌活水煎煮2次，第1次25分钟，第2次20分钟。过滤，合并滤液浓缩成稠膏(1∶2以上)。
(3)取天麻、地龙、僵蚕、水蛭、蝉退、洋金花六味药研细面过20～30目筛。
(4)取浓缩膏与六味细粉搅拌，低温干燥磨成粉，过60～80目筛后灭菌。
5、分剂量、装胶囊。
经浓缩与细粉搅拌灭菌后，总量是233克，为一个月的剂量。分装胶囊每粒胶囊含0.5克，一次3粒，日服3次，保持日服洋金花的剂量在0.1克，一日不超过0.3克。
6、禁忌：孕妇、小儿癫痫、青光眼忌用。
Claims (2)
1.治疗帕金森氏综合征的中药制剂，其特征在于制备该中药制剂的药效成分所用的原料药组成为：丹参25克 鸡血藤20克 怀牛藤15克 地龙15克 僵蚕12克 天麻12克 蝉蜕10克 石决明24克 葛根15克 炒白芍30克 钩藤12克 洋金花10克 大黄10克 甘草10克 羌活10克 肉苁蓉10克 水蛭10克
2、如权利要求1所述的治疗帕金森氏综合征的中药制剂，其特征在于包括下列步骤：
(1)筛选药物：
将配方中的药材去除杂质筛选上等药物并称足量。
(2)煎煮药液及浓缩：
取炒白芍、鸡血藤、丹参、葛根、肉苁蓉、怀牛膝、石决明、甘草八种药水煎2次，第1次1.5小时，第2次1小时；取大黄、钩藤、羌活3种药水煎2次，第1次25分钟，第2次20分钟。过滤，合并两组药液浓缩成稠膏。
(3)取天麻、地龙、僵蚕、水蛭、蝉蜕、洋金花六种药研细面过20-30目筛。
(4)取浓缩膏与六味细粉药搅拌，经低温干燥磨成粉过60-80目筛后灭菌。
(5)分剂量，装胶囊，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021266557A CN1313138C (zh) | 2002-07-24 | 2002-07-24 | 治疗帕金森氏综合征的中药制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021266557A CN1313138C (zh) | 2002-07-24 | 2002-07-24 | 治疗帕金森氏综合征的中药制剂 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1435213A CN1435213A (zh) | 2003-08-13 |
| CN1313138C true CN1313138C (zh) | 2007-05-02 |
Family
ID=27628591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021266557A Expired - Fee Related CN1313138C (zh) | 2002-07-24 | 2002-07-24 | 治疗帕金森氏综合征的中药制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1313138C (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1309408C (zh) * | 2005-01-19 | 2007-04-11 | 广东众生药业股份有限公司 | 治疗帕金森病及帕金森综合症的药物及其制备方法 |
| CN102091239B (zh) * | 2011-01-07 | 2012-07-04 | 孙建英 | 用于三叉神经痛的钩藤石酸汤 |
| CN109528951A (zh) * | 2018-12-14 | 2019-03-29 | 平启年 | 一种治疗帕金森病的中药组合物及其制备方法 |
| CN111366680B (zh) * | 2020-02-29 | 2022-09-23 | 陕西步长制药有限公司 | 一种物质含量测定方法及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086429A (zh) * | 1993-05-27 | 1994-05-11 | 高齐崧 | 硬瘫康的配制方法 |
| CN1257722A (zh) * | 1998-12-24 | 2000-06-28 | 赵徕淋 | 心脑疏通经络油及其制备方法 |
-
2002
- 2002-07-24 CN CNB021266557A patent/CN1313138C/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1086429A (zh) * | 1993-05-27 | 1994-05-11 | 高齐崧 | 硬瘫康的配制方法 |
| CN1257722A (zh) * | 1998-12-24 | 2000-06-28 | 赵徕淋 | 心脑疏通经络油及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1435213A (zh) | 2003-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1210047C (zh) | 治疗感冒的药物及其制备方法 | |
| CN111686147A (zh) | 一种杜仲提取物及其在治疗骨质疏松中的应用 | |
| CN1112836A (zh) | 治疗癫痫病的药物制剂新生克痫灵 | |
| CN101053621A (zh) | 一种治疗肥胖症的中药组合物及其制备方法 | |
| CN100528214C (zh) | 治疗癫痫病的胶囊及制备方法 | |
| CN1129130A (zh) | 一种治疗颈椎病的药物制剂 | |
| CN1313138C (zh) | 治疗帕金森氏综合征的中药制剂 | |
| CN105796739A (zh) | 一种制备治疗老年性骨折的中药组合物的方法 | |
| CN102100849B (zh) | 一种治疗腰椎间盘突出症的中药制剂及其制备方法 | |
| CN1324650A (zh) | 治疗顽症颈椎病的特效方药 | |
| CN1440804A (zh) | 一种降血脂的中药 | |
| CN1169546C (zh) | 治疗低血压疾病的中药 | |
| CN101439106A (zh) | 一种治疗中风病的药物 | |
| CN1111045C (zh) | 面瘫咀嚼剂及其制备方法 | |
| CN1279951C (zh) | 治疗甲亢及单纯性甲状腺肿大纯中药胶囊 | |
| CN1245197C (zh) | 治疗冠心病、病毒性心肌炎的中药制剂 | |
| CN1280835A (zh) | 一种治疗高脂血症的中药胶囊制剂 | |
| CN100344317C (zh) | 天麻胶囊及其制备方法 | |
| CN110464803A (zh) | 一种用于降低血压的中药组合物及其制备方法 | |
| CN1106848C (zh) | 一种治疗腰椎疾病的药物及其制备方法 | |
| CN1316989C (zh) | 治疗缺乏营养性疾病的胶囊及其制备工艺 | |
| CN1168483C (zh) | 一种治疗心脏病的药物 | |
| CN1060956C (zh) | 一种用于治疗高脂血症的药物调脂片及其制备方法 | |
| CN113041322A (zh) | 一种治疗帕金森病的中药及其制备方法与应用 | |
| CN119157996A (zh) | 一种具有补肾壮阳的口服制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |